Abstract 960P
Background
HCC is an aggressive malignancy, accounting for ∼90% of primary hepatic cancers. While surgical resection and liver transplantation (Tx) can be curative, 8-20% of post-Tx and 40-70% of post-resection patients recur. Here we sought to analyze the utility of longitudinal testing with ctDNA in patients (pts) with HCC.
Methods
This multicenter study retrospectively analyzed 227 plasma samples from 66 pts with HCC. The curative-intent surgeries included liver Tx (41/66, 62%) and hepatectomy (23/66, 34%); two pts (3%) who were inoperable received liver directed and systemic targeted therapy. Five of the 41 post-Tx pts received additional resection for oligometastatic recurrence prior to ctDNA testing. The cohort was analyzed based on 3 mutually exclusive sub-cohorts: Cohort A (N=34): recurrence monitoring after curative liver Tx; Cohort B (N=25): recurrence monitoring after curative-intent surgical resection; Cohort C (N=7): pts with known recurrence monitored for treatment response/disease progression. Longitudinal ctDNA testing was performed using the SignateraTM bespoke mPCR NGS assay.
Results
The cohort distribution included: 28 (42.4%) / 21 (31.8%) / 7 (10.6%) / 9 (13.6%) stage I/II/III/IV pts with a median age of 67 years (range: 21-84); median follow-up of 584 days (range: 79 - 1537). In cohort A, all patients were ctDNA-negative and remained recurrence-free.In cohort B, postsurgical ctDNA was detected in 9 (36%) patients, 6 experienced clinical recurrence and 3 had limited follow-up. The median lead time of ctDNA detection over clinical recurrence was 52 days (range: 0-262). Among the ctDNA-negative patients (N=16), only one pt experienced clinical recurrence; this was >1 year after the last ctDNA test. In cohort C, on-treatment ctDNA dynamics were concordant with treatment response in 4 pts as measured by imaging. The remaining 3 pts were persistently ctDNA-negative on/shortly after systemic therapy.
Conclusions
Longitudinal testing with ctDNA is critical in identifying early recurrence post surgical resection. Similarly, monitoring treatment response in the palliative setting can help resolve ambiguous imaging results.
Clinical trial identification
N/A
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
C. Brdiges: Financial Interests, Institutional, Advisory Board, Full-time employment and stock or option to own stock at Natera, Inc. Name: Antony Tin: Natera, Inc.. T. Tin, C. Brewer, A. Jurdi, M.C. Liu: Financial Interests, Personal and Institutional, Advisory Board: Natera Inc. All other authors have declared no conflicts of interest.
Resources from the same session
1009P - Network meta-analysis of first-line systemic therapies for advanced hepatocellular carcinoma: A comparison of objective response rates
Presenter: Gagandeep Kaur
Session: Poster session 18
1010P - A parametric network meta-analysis of first-line systemic therapies for advanced hepatocellular carcinoma related to overall survival
Presenter: Akanksha Sharma
Session: Poster session 18
1011P - A prospective study of TACE combined with lenvatinib plus sintilimab for HCC with portal vein tumor thrombus
Presenter: Xiaoyan Ding
Session: Poster session 18
1012P - First-in-human study of ABSK-011, a novel, highly selective fibroblast growth factor receptor (FGFR) 4 inhibitor for treating advanced hepatocellular carcinoma (HCC) with FGF19 overexpression
Presenter: Ann-Lii Cheng
Session: Poster session 18
1013TiP - Refinement and validation of a comprehensive clinical diagnostic model (GAMAD) for early detection of hepatocellular carcinoma: A multicenter, prospective study protocol
Presenter: Tian Yang
Session: Poster session 18
1014TiP - Efficacy and safety of recombinant human adenovirus type 5 injection combined with transhepatic arterial embolization sequential thermal ablation for medium-and high-risk recurrent liver cancer: a prospective, open-label, randomized controlled study
Presenter: Jianjun Li
Session: Poster session 18
1015TiP - A Prospective, phase II clinical study of tislelizumab monotherapy or in combination with lenvatinib for neoadjuvant treatment of resectable hepatocellular carcinoma
Presenter: Tianqiang Song
Session: Poster session 18